Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABUCCO neoadjuvant ipilimumab and nivolumab study in high-risk resectable urothelial cancer
NL-OMON55844Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ipilimumab and nivolumab in transitional cell carcinoma (TCC) (3 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety in cohort 1 and Most effective regimen in cohort 2. Started Feb 2018; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON55844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55844.